Literature DB >> 16230779

RET polymorphisms and sporadic medullary thyroid carcinoma in a Portuguese population.

Patrícia Costa1, Rita Domingues, Luís G Sobrinho, Maria João Bugalho.   

Abstract

The genetic basis of the sporadic form of medullary thyroid carcinoma, derived from "C" cells, is still poorly understood. Somatic mutations of RET proto-oncogene have been reported at a variable frequency ranging from 23% to 69%. The hypothesis that low penetrance factors, such as polymorphisms, might contribute to the phenotype of this neoplasm has been addressed in a few studies conducting to conflicting results. Herein, we studied 100 individuals (50 patients and 50 controls) aiming to compare the frequencies of G691S, L769L, S836S, and S904S RET polymorphisms observed in patients with respect to controls. Furthermore, meta-analysis of published studies including the present results was conducted. To test the contributory role of the above polymorphisms for the development of "C"-cell hyperplasia, we studied a group of 10 individuals selected for having a positive pentagastrin test despite the absence of a RET germline mutation. An over-representation of the G691S polymorphism, particularly in females, was observed in patients with respect to controls, although not reaching the level of significance. Allelic frequencies of the other three polymorphisms were not different in patients and controls. Results obtained in the admittedly small group of individuals with a positive pentagastrin test are unlikely to support a major influence of any polymorphism in the development of "C"-cell hyperplasia. The meta-analysis provided evidence for a significant association of the S691 allele with MTC (odds ratio 1.54, 95% confidence interval 1.12-2.12, p=0.008) and found no significant associations for the other polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16230779     DOI: 10.1385/ENDO:27:3:239

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  41 in total

1.  RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease.

Authors:  S Borrego; A Ruiz; M E Saez; O Gimm; X Gao; M López-Alonso; A Hernández; F A Wright; G Antiñolo; C Eng
Journal:  J Med Genet       Date:  2000-08       Impact factor: 6.318

2.  RET polymorphisms in codons 769 and 836 are not associated with predisposition to medullary thyroid carcinoma.

Authors:  Małgorzata Wiench; Jan Włoch; Zbigniew Wygoda; Elzbieta Gubała; M Oczko; A Pawlaczek; D Kula; D Lange; B Jarzab
Journal:  Cancer Detect Prev       Date:  2004

3.  Influence of age and sex on plasma calcitonin in human beings.

Authors:  L J Deftos; M H Weisman; G W Williams; D B Karpf; A M Frumar; B J Davidson; J G Parthemore; H L Judd
Journal:  N Engl J Med       Date:  1980-06-12       Impact factor: 91.245

4.  Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma.

Authors:  F Lesueur; M Corbex; J D McKay; J Lima; P Soares; P Griseri; J Burgess; I Ceccherini; S Landolfi; M Papotti; A Amorim; D E Goldgar; G Romeo
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

5.  Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC.

Authors:  S J Laken; G M Petersen; S B Gruber; C Oddoux; H Ostrer; F M Giardiello; S R Hamilton; H Hampel; A Markowitz; D Klimstra; S Jhanwar; S Winawer; K Offit; M C Luce; K W Kinzler; B Vogelstein
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

6.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.

Authors:  C Eng; D Clayton; I Schuffenecker; G Lenoir; G Cote; R F Gagel; H K van Amstel; C J Lips; I Nishisho; S I Takai; D J Marsh; B G Robinson; K Frank-Raue; F Raue; F Xue; W W Noll; C Romei; F Pacini; M Fink; B Niederle; J Zedenius; M Nordenskjöld; P Komminoth; G N Hendy; L M Mulligan
Journal:  JAMA       Date:  1996-11-20       Impact factor: 56.272

7.  Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.

Authors:  A Ruiz; G Antiñolo; R M Fernández; C Eng; I Marcos; S Borrego
Journal:  Clin Endocrinol (Oxf)       Date:  2001-09       Impact factor: 3.478

8.  Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism.

Authors:  L G Goldfarb; R B Petersen; M Tabaton; P Brown; A C LeBlanc; P Montagna; P Cortelli; J Julien; C Vital; W W Pendelbury
Journal:  Science       Date:  1992-10-30       Impact factor: 47.728

9.  Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.

Authors:  J Zedenius; G Wallin; B Hamberger; M Nordenskjöld; G Weber; C Larsson
Journal:  Hum Mol Genet       Date:  1994-08       Impact factor: 6.150

10.  Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.

Authors:  C Romei; R Elisei; A Pinchera; I Ceccherini; E Molinaro; F Mancusi; E Martino; G Romeo; F Pacini
Journal:  J Clin Endocrinol Metab       Date:  1996-04       Impact factor: 5.958

View more
  10 in total

1.  The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland.

Authors:  Maria Sromek; Malgorzata Czetwertyńska; Elzbieta Skasko; Joanna Zielińska; Dorota Czapczak; Jan Steffen
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

2.  RET proto-oncogene mutations are restricted to codon 618 in Cypriot families with multiple endocrine neoplasia 2.

Authors:  V Neocleous; N Skordis; G Portides; E Efstathiou; C Costi; N Ioannou; M Pantzaris; V Anastasiadou; C Deltas; L A Phylactou
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

3.  Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients.

Authors:  A Gursoy; M F Erdogan; G Erdogan
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

4.  Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk.

Authors:  Yuanqi Zhang; Sanming Wang; Xiaodong Chen; Shengchao Huang; Jianwen Li
Journal:  Tumour Biol       Date:  2014-04-04

5.  RET gene mutations and polymorphisms in medullary thyroid carcinomas in Indian patients.

Authors:  B P Sharma; D Saranath
Journal:  J Biosci       Date:  2011-09       Impact factor: 1.826

6.  A complex endocrine conundrum.

Authors:  G Bano; V Siedel; N Beharry; P Wilson; T Cranston; S Hodgson
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

7.  The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.

Authors:  Carla Colombo; Emanuela Minna; Maria Grazia Rizzetti; Paola Romeo; Daniele Lecis; Luca Persani; Piera Mondellini; Marco A Pierotti; Angela Greco; Laura Fugazzola; Maria Grazia Borrello
Journal:  Orphanet J Rare Dis       Date:  2015-03-01       Impact factor: 4.123

8.  Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: Results from the largest MTC cohort and meta-analysis.

Authors:  Vasudha Mishra; Pradnya Kowtal; Pallavi Rane; Rajiv Sarin
Journal:  Cancer Med       Date:  2019-08-13       Impact factor: 4.452

9.  Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma.

Authors:  Anna Skalniak; Małgorzata Trofimiuk-Müldner; Elwira Przybylik-Mazurek; Alicja Hubalewska-Dydejczyk
Journal:  Int J Mol Sci       Date:  2021-10-30       Impact factor: 5.923

10.  The synergy of germline C634Y and V292M RET mutations in a northern Chinese family with multiple endocrine neoplasia type 2A.

Authors:  Zheng Yang; Xinmeng Qi; Neil Gross; Xiujuan Kou; Yunlong Bai; Yaru Feng; Bochun Wang; Mark E Zafereo; Guojun Li; Chuanzheng Sun; Huihui Li; Xiaohong Chen; Zhigang Huang
Journal:  J Cell Mol Med       Date:  2020-09-29       Impact factor: 5.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.